Table 1.
Patient characteristics and effects of treatments including previous and concomitant treatments
| Treatment | Number of ulcers during treatment | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. | Activity score | Systemic sclerosis (SSc) type | DD (years) | Age (years) | Previous and concomitant | Start | Duration (months) | Dosage (mean, mg/day) | Start | Min | End | Compl heal | New | Side effects |
| 1 | 4.5 | Diff | 2 | 69 | CCB, PC (4), PX | January | 2§ | 50 | 1 | 0 | 0 | 1 | 0 | No |
| 2 | 2.0 | Lim | 41 | 51 | SL, CCB, PC (2), ASA | October | 1‡ | 150 | 1 | 1 | 1 | 0 | 0 | No |
| 3 | 3 | Lim | 0.5 | 40 | PC (3.5), CCB, SL, P (7.5) | September | 3§ | 150 | 3 | 1 | 2 | 2 | 1 | No |
| 4 | 3.0 | Diff | 25 | 54 | ACE, CCB, ASS, P (2.5) | February | 6 | 50 | 1 | 0 | 0 | 1 | 0 | No |
| 5 | 2.5 | Lim | 11 | 59 | PX, PC (3), CCB, HQ, P (4), | February | 6 | 150 | 1 | 0 | 0 | 1 | 0 | E, Fl, Pa, Dizz, Rx |
| 6* | 0.5 | Diff | 5 | 55 | PC (1.5), SG, CCB, AB, ACE | April | 2.5† | 75 | 2 | 0 | 0 | 2 | 0 | Dys, E, WI |
| 7 | 1.0 | Lim | 0.5 | 39 | PC (5), CCB, ATB, P (7) | January | 6 | 100 | 3 | 0 | 0 | 4 | 1 | Fl, Pa, RRR, Rx |
| 8 | 5.0 | Diff | 5 | 58 | AA, CCB, ACE, PC (4) | October | 6 | 150 | 2 | 0 | 1 | 2 | 1 | Fl |
| 9 | 1.0 | Lim | 3 | 29 | CCB, PX, ASA, | January | 6 | 150 | 2 | 1 | 1 | 1 | 0 | E |
| 10* | 1.0 | Lim | 6 | 70 | PC (4), SG, CCB, ACE AZA, P (5), PX | August | <1† | 50 | 5 | 5 | 5 | 0 | 0 | AF, Dizz |
| 11 | 1.0 | Lim | 6 | 48 | PP, PC (2), PX, CCB, AC | May | <1‡ | 75 | 2 | 2 | 2 | 0 | 0 | No |
| 12 | 2.5 | Diff | 2 | 54 | CCB, ACE, PC (2.5), AB, ATB | May | 6 | 125 | 5 | 0 | 2 | 5 | 2 | RRR |
| 13 | 2.0 | Diff | 11 | 43 | PC (6), CCB, PX, P (5) | August | 6 | 50 | 2 | 0 | 3 | 2 | 3 | E, Fl, Pa, MP |
| 14 | 1.0 | Diff | 7 | 43 | PC (3), CCB, ASA, P (5) | April | 6 | 75 | 4 | 1 | 2 | 3 | 1 | WI, Pa, RRR |
| 15 | 2.0 | Lim | 9 | 60 | SG, PC (3), CCB, ACE | January | 6 | 150 | 6 | 2 | 2 | 5 | 1 | No |
| 16 | 2.5 | Diff | 22 | 51 | SG, PC (3), PX, ASA | February | 4§ | 150 | 4 | 2 | 2 | 3 | 1 | No |
| 17 | 3.0 | Diff | 17 | 65 | PC (2), PX, CCB, CYC, P (10) | May | 6 | 100 | 6 | 2 | 2 | 5 | 1 | No |
| 18 | 1.5 | Lim | 14 | 38 | SG, PC (5), CCB, PX, PP, P (7.5) | March | 6 | 150 | 5 | 0 | 0 | 5 | 0 | No |
| 19 | 2.0 | Lim | 1 | 42 | CYC, CCB, PC (2), AC | June | 6 | 150 | 2 | 0 | 0 | 2 | 0 | No |
SSc type: lim, limited; diff, diffuse.
Indicates male patients.
Indicates cessation of treatment due to side effects.
Indicates cessation of treatment due to other events with possible impact on the effect of treatment (ulcer infection, cyclophosphamide use).
Indicates patients with development of new digital ulcer or calcinosis and no significant improvement by treatment.
AA, autoamputation; AB, α blocker; AC, anticoagulation; ACE, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; ASA, acetyl salicylic acid; ATB, angiotensin receptor blocker; AZA, azathioprine; BWI, body weight increase; CCB, calcium channel blockers; compl heal, number of ulcers completely healed; CYC, cyclophosphamide; DD, disease duration; Dizz, dizziness; Dys, dyspnoea; E, Oedema; Fl, flush; HQ, hydroxycloroquine; MP, muscle pain; P, prednisone (mg/day); Pa, palpitations; PC, intravenous prostacyclin (weeks with maximally tolerated dose for 6 h/day); PP, plasmaphereses; PX, pentoxyphylline; RRR, reduction of RR (arterial hypertension) medication; Rx, reflux; SG, surgery; SL, sympathicolysis.